Best Clinical Trial Software of 2026: One Pick for Each Category

There is no single piece of clinical trial software. What people call a trial platform is really a stack of eight to ten separate systems in practice, drawn from eleven possible categories, each solving a different problem, sold by different vendors, and bought by different people inside the same organization. The data manager picks the EDC. The regulatory lead picks the eTMF. The site coordinator lives in a CTMS that nobody at the sponsor has ever logged into.

Most roundups ignore this and hand you ten products that do overlapping things, which is useless when you are trying to work out what you are actually missing. So this guide is organized by category instead. Eleven categories, one recommended tool in each, picked because it is the best at that one job.

Every vendor link below was checked before publication, and where a product has been acquired or renamed we say so in its section. This industry consolidates fast enough that a roundup written from other roundups will send you to at least one company that no longer exists.

How to evaluate any category

Before you compare products inside a category, work out whether you need that category at all. A single site running three studies a year does not need an eTMF or a safety database. A sponsor running forty trials needs both, plus a randomization system it can trust at three in the morning. Buying software for a scale you have not reached is the most common and most expensive mistake in this market.

Once you know the category is real for you, these five questions separate the vendors.

• How long does a study take to build? The gap here is enormous. Some platforms let a study manager configure forms without writing code and go live in weeks. Enterprise systems often need a specialist and a longer validation cycle. Ask each vendor for that number against a study of your own complexity; vendors tend to quote their best case by default.
• Who actually uses it every day? Coordinators and site staff spend far more hours inside these systems than sponsors ever do. If site staff already know a platform, training cost drops sharply and data quality tends to follow. This single factor explains most of why incumbents keep winning.
• What happens during a protocol amendment? Amendments are normal. What matters is whether deploying one takes hours or months, and whether sites lose access while it happens.
• Does it genuinely share a database with its neighbors? Nearly every vendor markets a unified platform, but the meaning varies. Modules on one system remove reconciliation work. Separate products stitched together with integrations do not, whatever the sales deck says.
• Who owns it now? This industry consolidates constantly. The tool you shortlist may have been acquired twice since the review you read. Check the vendor’s own site, not a comparison article, before you take a demo.

The eleven categories at a glance

Best clinical trial software of 2026 by category

1. Electronic data capture: Medidata Rave

Key features:

• Protocol amendments without downtime
• EHR to EDC population through Rave Companion
• Rave Lite for Phase I, Phase IV, and device studies
• Connected eCOA, eConsent, RTSM, and imaging modules

The EDC is where participant data lives: lab values, adverse events, visit outcomes, everything a regulator will eventually ask to see. It is the first system most organizations buy and the hardest to replace once sites learn it.

Rave is the closest thing the industry has to a default. Medidata cites the 2025 ISR Benchmarking Report, which surveys sponsors independently, as rating Rave the most preferred EDC. That reputation has a practical payoff, because a large share of experienced coordinators have already worked in Rave and need almost no training. The capability worth singling out is mid study change handling: Medidata states amendments deploy with no downtime, reaching thousands of patients in hours rather than months. For adaptive designs, that alone can justify the platform.

Best for: sponsors and CROs whose sites already know the system. Alternatives: Veeva Vault CDMS, Oracle Clinical One, Medrio.

Pricing: not publicly disclosed – connect with a Medidata specialist; no pricing page.

Free trial: none. Access starts with a demo request.

Pros:

• EHR-to-EDC population through Rave Companion cuts manual data entry at the source
• Rated the most preferred EDC in the 2025 ISR Benchmarking Report, an independent survey of sponsors (vendor-cited)
• G2 reviewers point to running multiple roles and tabs under one login as a real usability advantage over competing EDCs

Cons:

• Cost is G2’s most common complaint – reviewers describe it as expensive, particularly for smaller companies
• A Reddit clinical-research thread flags it as less user-friendly than some newer EDC entrants

2. eClinical platform for small teams: Castor

Key features:

• Study build without writing code
• EDC, CDMS, eCOA, ePRO, and eConsent on one system
• Castor Catalyst for AI clinical data extraction
• Registry, post market, and real world evidence studies

Enterprise EDCs assume you have a clinical programming function. Most biotech, device, and academic teams do not, and they need one system that covers capture, consent, and outcomes without a six month implementation.

Castor dropped the EDC from its name as the product outgrew the category. By its own published figures it has supported more than 17,000 studies across over 170 countries, with low complexity studies launching in three to four weeks. The reason it belongs here in 2026 is Castor Catalyst, an AI layer that reads source documents such as scans, EHR exports, and physician notes, then proposes structured values for the case report form. Every value carries a confidence score, sits beside its source, and needs a human reviewer to accept or reject it before it enters the record. Castor reports that this cuts per chart review from roughly 39 minutes to about 6, at an error rate under 0.7 percent against 6.6 percent for manual review. Those are vendor published numbers and deserve the scrutiny you would give any vendor benchmark, but the human in the loop design is the right architecture and the claimed gains are large enough to be worth testing.

Best for: biotech, medical device, and academic teams that want modern tooling without an enterprise implementation. Alternatives: Medrio, OpenClinica, Anju eClinical Suite.

Pricing: custom-quoted, but more transparently than most of this list – Castor publishes a 5-step pricing process on its own site and promises a proposal within 5 business days. No published numbers.

Free trial: yes – a genuine self-serve signup (“Try Castor for free”), the only tool in this guide besides actiTIME that offers one.

Pros:

• Low-complexity studies can launch in three to four weeks, by Castor’s own figures
• G2 and Capterra reviewers rate it 4.7, citing ease of use and the ability to filter by site or patient
• Castor Catalyst keeps a human reviewer in the loop on every AI-extracted value rather than auto-accepting it

Cons:

• Capterra reviewers note session logouts as a recurring friction point
• Castor Catalyst’s efficiency figures (about 39 minutes to about 6 per chart review) are vendor-published, not independently audited

3. Trial master file: Veeva Vault eTMF

Key features:

• Expected Document Lists for automated completeness checks
• Risk based quality control workflows
• Version control and real time co authoring
• TMF exchange between sponsors and partners

The trial master file is the evidence that your trial was run properly. When an inspector arrives, the TMF is what they read. Running it on shared drives is how organizations end up spending months reconstructing documents before an inspection.

Veeva Vault eTMF is the category leader for enterprise sponsors and CROs; more than 500 companies now use at least one Veeva Vault Clinical solution. What it changes is the rhythm of TMF work, which stops being a filing exercise and becomes a continuous one. Expected Document Lists flag what is missing while the trial is still running, and risk based quality control sends reviewers to the documents most likely to matter instead of checking everything equally. If your organization already runs Veeva for regulatory documents or study startup, the case is close to automatic.

Best for: sponsors and CROs that need continuous inspection readiness. Alternatives: MasterControl, Viedoc.

Pricing: not publicly disclosed – contact sales; no pricing page.

Free trial: none. Demo-led.

Pros:

• Expected Document Lists and risk-based quality control are named, specific mechanics, not vague feature language
• G2 and Software Advice reviewers consistently cite reliability at scale, with one noting it “doesn’t crash like other systems”
• More than 500 companies now use at least one Veeva Vault Clinical solution, by Veeva’s own figures

Cons:

• Software Advice and Reddit reviewers both flag cost as a barrier for smaller organizations, including the need for paid contractors to produce training materials

4. Randomization and trial supply: Suvoda

Key features:

• Interactive response technology for randomization
• Drug supply forecasting and dispensing
• Deployment in as little as two weeks
• Built for oncology, central nervous system, and rare disease trials

Randomization and trial supply management, known as RTSM or IRT, decides which arm a patient enters and makes sure the right drug is at the right site when they arrive. It is unglamorous and it is the system most likely to stop a trial dead when it fails.

Suvoda specializes in exactly the trials where this goes wrong: complex oncology, central nervous system, and rare disease protocols with intricate randomization schemes and fragile supply chains. The company reports support for more than 6,000 trials across 115 countries, RTSM deployment in as little as two weeks, and that 34 percent of FDA-approved trials since 2024 ran on its technology. Treat that last figure as a fact about who hires Suvoda rather than proof of what Suvoda causes, but the speed of deployment is a genuine differentiator in a category where twelve week builds are normal.

Best for: sponsors running complex randomization or constrained drug supply. Alternatives: 4G Clinical Prancer, Oracle Clinical One RTSM, Medidata RTSM.

Pricing: not publicly disclosed – demo request only; no pricing page.

Free trial: none.

Pros:

• Deployment claimed in as little as two weeks, with kickoff to UAT inside that window by Suvoda’s own figures
• 34 percent of FDA-approved trials since 2024 ran on Suvoda’s technology, by its own figures – a fact about who hires Suvoda, not proof of what Suvoda causes
• Now integrated with Greenphire’s payment platform under the same ownership, syncing payments to eCOA activity completion

Cons:

• Independent review coverage is thin – G2 shows a single review for this product line, so third-party validation is essentially absent

5. Patient outcome data: Signant Health

Key features:

• eCOA covering patient, clinician, and observer reported outcomes
• Bring your own device and provisioned device options
• Data quality controls for endpoint reliability
• More than 30 years of clinical trial experience

Electronic clinical outcome assessment, or eCOA, captures what the patient reports: symptoms, quality of life, pain scores, the endpoints that increasingly decide whether a drug is approved. Getting it wrong quietly corrupts your primary endpoint, which is not a thing you discover early.

Signant Health is a specialist rather than a platform vendor with an eCOA module bolted on, and in this category the specialists still lead. The interesting decision it forces is modality: whether participants use their own phones or devices you provision. Signant supports both, and its guidance on choosing between them is more candid than most vendor material, which tells you something about how contested that choice actually is in practice.

Best for: sponsors where patient reported outcomes carry a primary or key secondary endpoint. Alternatives: Clario, YPrime, Medidata eCOA, Castor.

Pricing: not publicly disclosed – “Discuss Trial” leads to a sales contact; no pricing page.

Free trial: none.

Pros:

• More than 50 in-house scientists and clinicians support protocol and outcome-measure design, a differentiator from pure-technology eCOA vendors
• Associated with 25 percent of novel drug approvals across the FDA and EMA from 2020 to 2025, by its own figures
• An independent vendor comparison (Curebase) credits it with strong clinical-science depth and data-quality focus among eCOA vendors

Cons:

• A Reddit clinical-research thread specifically criticizes device and platform usability
• The same third-party comparison notes it is less flexible than newer platforms for fast study changes

6. Drug safety and pharmacovigilance: Oracle Safety One Argus

Key features:

• Global adverse event case processing
• Automated case intake and E2B regulatory reporting
• Signal detection through Oracle Empirica
• Post marketing surveillance

A safety database records adverse events, processes them into regulatory cases, and files them with health authorities inside legally binding deadlines. Miss those deadlines and the consequences are regulatory, not commercial.

Argus, now sold as Oracle Life Sciences Safety One Argus, is the most widely deployed pharmacovigilance platform in the industry, and its ubiquity is self reinforcing: the people you hire already know it. It handles high volume case processing, automated intake, and expedited reporting, while Oracle Empirica covers signal detection across data sources. This is a category where the boring, established choice is usually the correct one, because the cost of a failure here is regulatory action, not lost productivity.

Best for: any organization with post marketing products or regulatory reporting obligations. Alternatives: ArisGlobal LifeSphere, Veeva Vault Safety.

Pricing: not publicly disclosed – “Request a demo” is the only CTA on Oracle’s own page, with no pricing figures.

Free trial: none found on Oracle’s own pharmacovigilance page.

Pros:

• Automated case intake and E2B regulatory reporting cover the deadline-driven part of the job directly
• Oracle Empirica adds signal detection across data sources inside the same platform
• Wide deployment across the industry means new hires are more likely to already know the system

Cons:

• No independent reviews or public pricing could be found for this specific product – third-party coverage is thin compared to the other tools in this guide

7. Site trial management: Clinical Conductor

Key features:

• Visit scheduling and participant engagement
• Financial analytics and invoicing against procedures
• CCText for participant messaging
• CCPay for participant payments

A CTMS runs the operational business of a research site: who is enrolled, when visits happen, what each procedure earns, and whether the site is being paid. It is the system sponsors most often forget exists, and the one site directors care about most.

Clinical Conductor is built for sites rather than sponsors, and the financial layer is what site directors buy it for. Budget tracking, invoicing against completed procedures, and cross study reporting give a site network real visibility into which trials are worth running at all. Advarra acquired the original maker, Bio-Optronics, in 2021, and the product now sits inside Advarra’s wider site technology portfolio, which matters if you also use Advarra for IRB services.

Best for: hospitals, health systems, cancer centers, and site networks running many studies at once. Alternatives: RealTime-CTMS, Anju CTMS Master.

Pricing: not publicly disclosed – demo request only; no pricing page.

Free trial: none.

Pros:

• CCText and CCPay are named, specific modules – two-way texting and real-time debit reimbursement – not vague feature bullets
• G2 reviewers describe it as easy to learn, with real time savings for site staff
• ISO 27001 and SOC 2 Type 2 certified

Cons:

• Capterra reviewers report a quality decline since Advarra’s 2021 acquisition, including slower customer service

8. Site eRegulatory and eISF: Florence eBinders

Key features:

• Electronic investigator site file and participant binders
• Remote monitor access to source documents
• Audit trails and electronic signatures
• Electronic logs replacing paper

The investigator site file, or eISF, is the site’s own regulatory record, the local counterpart to the sponsor’s TMF. Historically it was a wall of binders, and monitors flew across the country to read them.

Florence eBinders digitizes that file, and its market position is unusually clear: Florence reports more than 88,000 study sites across 90+ countries running trials on its platform, with a 90 percent eISF adoption rate among them. The feature that changed site economics is remote monitor access. A monitor reviews documents without traveling, which removes cost from the sponsor and interruption from the site. If you run a site still working from paper binders, this category will return more time per dollar than almost anything else on this list.

Best for: research sites moving off paper regulatory binders. Alternatives: Complion, Veeva SiteVault.

Pricing: not publicly disclosed – demo or product tour only; no pricing page.

Free trial: none.

Pros:

• 88,000+ sites across 90+ countries and a claimed 90 percent eISF adoption rate among them, by Florence’s own figures
• Capterra and Software Advice reviewers rate it 4.5, citing easier file management and customization
• Integrates with an existing CTMS or EMR rather than replacing it

Cons:

• Reddit reviewers call it pricey, with documents that can’t be uploaded in bulk and review times that run long
• Capterra reviewers note some features sit behind a premium plan, plus frequent re-logins

9. Participant payments: Greenphire

Key features:

• Real time payments in local currency
• Debit card, virtual card, and bank deposit options
• Travel and expense reimbursement
• Reporting for sponsors and CROs

Participants incur real costs to join a trial: travel, parking, lost wages, childcare. Paying them slowly, or making a coordinator process reimbursements by hand, is a retention problem disguised as an administrative one.

Greenphire is the established name here, and its ClinCard is familiar enough that many academic medical centers name it directly in their participant payment procedures. Payments reach participants in local currency through their preferred method, and the site workload of executing them largely disappears. Note that Greenphire merged with Suvoda in 2025, so this category and randomization now sit under one owner. That is convenient if you want both and worth knowing if you would rather not concentrate two systems with one vendor.

Best for: sponsors and sites where participant burden threatens retention. Alternatives: Advarra CCPay, Mural Health.

Pricing: not publicly disclosed – demo request only; no pricing page.

Free trial: none.

Pros:

• Pays in 30+ currencies with 24/7 local-language support
• Micropayments trigger automatically off eCOA activity completion, a concrete integration mechanic rather than a manual process
• Applied Clinical Trials Online reports a top-5 pharma company cut administrative work by up to 90 percent and costs by up to 60 percent after adoption – a trade-press-reported figure, though it originates from a vendor-supplied case study

Cons:

• Now folded into Suvoda’s broader portfolio – a narrow, single-function tool rather than a platform
• No public pricing, same as every enterprise tool in this guide

10. Recruitment and enrollment: EnrollNow

Key features:

• Participant prescreening workflows
• Visit scheduling and engagement
• Study management for research teams
• Secure handling of participant data

Recruitment is the reason most trials run late. No amount of elegant data capture helps a study that cannot fill its arms, and enrollment work rarely fits neatly into either the EDC or the CTMS.

EnrollNow is the product formerly known as Ripple Science, recently rebranded. It does one thing and leaves the rest alone: moving people through prescreening, enrollment, scheduling, and ongoing engagement. Built by researchers for researchers, it is most at home in clinical, translational, and social science studies. If your data systems are settled and your bottleneck is the pipeline of participants, not the data coming out of them, a focused tool here will do more for the study than another platform module.

Best for: academic and translational research teams where enrollment is the constraint. Alternatives: OpenClinica Study Hub, the recruitment tools inside Clinical Conductor.

Pricing: not publicly disclosed – “Talk to an Expert” is the only stated path in.

Free trial: none found – demo-led despite the lighter-weight target market.

Pros:

• Built at the University of Michigan specifically for research recruitment, not adapted from a generic CRM
• Its predecessor brand, Ripple, holds a 4.8 rating across 32 Capterra reviews – a strong independent signal for a niche tool
• HIPAA-compliant and SOC 2 certified

Cons:

• A Capterra reviewer notes the login page isn’t discoverable through a normal search engine query, a real usability gap
• The recent rebrand from Ripple Science splits its review history across two names

11. Time, cost, and project operations: actiTIME

Key features:

• Clinical trial timesheets tracked by customer, project, and task
• Cost of Work, Billing Summary, and Profit/Loss reports per study
• Clinical trial budget tracking with overrun alerts
• PDF invoices generated from billable time
• Self hosted option for data residency

Every category above manages the trial. None of them tells you what the trial costs to run. Which hours went into which study, what those hours cost, and whether the contract covers them sits outside the EDC and outside most CTMS reporting — budget tracking is the piece most roundups skip entirely. This is where contract research organizations and research sites lose margin without noticing, and it is a category, not an afterthought.

The problem is measurable. A 2024 workload study in the Journal of Clinical and Translational Research found that coordinator workload differs significantly between federally funded and industry sponsored protocols, and that trial complexity scores predict coordinator hours well enough to plan capacity from them. In other words, studies do not cost what the budget template assumed they would, and the only way to find out is to record the hours against the study.

actiTIME is time tracking software for clinical trials that connects hours to financial outcomes. Be clear about what it is: a commercial and operational tool, not a replacement for your EDC or CTMS, and not a regulated system of record. It answers the money question the clinical stack leaves open. Research staff fill in a clinical trial timesheet week by week, or log exact start and stop intervals on a calendar view, with a mobile app for capturing time between visits and a Chrome extension with an automatic timer for desk work.

Why actiTIME is the right choice for clinical trial organizations

1. It turns hours into money.

   Most time trackers stop at a total. actiTIME applies a cost of work rate per employee and a billing rate per type of work, so the Cost of Work report shows staff expense per study, the Billing Summary shows what is billable, and the Profit/Loss report compares the two by customer, project, or task. That turns a timesheet into clinical trial financial management, and it is the one feature that separates it from the free timers most sites start with.

2. Its structure already matches how a study is organized.

   Work is arranged as customer, then project, then task, and all three labels are renameable in settings. Sites map them to sponsor, protocol, and visit or procedure. Nothing has to be forced into a shape built for software teams, which is the usual failure mode when research organizations adopt a generic project tool.

3. Budgets mirror how trial budgets are actually negotiated.

   Cost, billing, and time budgets can be set at the customer, project, or task level, each with a progress bar that turns red on overrun. Because budgets attach at task level, the unreimbursed work that steadily erodes site margin, screen failures and monitoring visits above all, stops being a hunch and starts being a number.

4. Closed periods stay closed.

   Managers can require timesheet approval and then lock time entries once a period closes, so figures cannot shift after an invoice has gone out. Anyone who has reconciled clinical research billing against a moving timesheet will understand why this matters.

5. It runs where your data has to live.

   Academic centers and organizations with data residency obligations can install actiTIME on their own infrastructure instead of a vendor cloud, for a one time fee. Few tools that also handle costing and invoicing will let you do that.

The effort reporting angle matters for anyone holding federal awards. Under 2 CFR 200.430, salaries charged to a federal award must be supported by records that accurately reflect the work performed. actiTIME produces those underlying time records and the reports that summarize them by project and person. Formal effort certification still belongs in your research administration system, and actiTIME should not be treated as a validated repository for regulated trial data, but the hours it captures are the raw material those processes run on.

Track hours spent on clinical trials with actiTIME to see what each study really costs and which ones stay profitable

Try Free

Best for: CRO and site operations and finance teams that need to know study cost, billable hours, and profitability per protocol. Alternatives: general purpose time trackers and clinical trial budget software, though the former stop at recording hours and the latter rarely capture staff time at all.

Pricing: public, unlike everything else on this list – free for up to 3 users; 1–40 users at $6/user/month billed annually; 41–200 users at $5/user/month billed annually; 200+ users at $1,250/month billed annually; self-hosted from $120/user as a one-time purchase. Every version includes human support and free onboarding.

Free trial: 30 days, full feature access, no credit card required – a site can pilot it on one protocol before committing.

Pros:

• The only tool in this guide besides Castor with a genuine self-serve trial, and the only one with fully public pricing
• Cost of Work, Billing Summary, and Profit/Loss reports turn logged hours into a real margin figure per protocol, not just a total
• Self-hosted option available for organizations with data residency requirements

Cons:

• Not a regulated system of record, and not a substitute for an EDC, CTMS, or any of the ten categories above it
• No native EHR integration and no clinical-data validation – it answers the cost question, not the operational or regulatory ones

actiTIME enables us to balance workload better

I found in actiTIME all the requirements I was looking for. We are getting a lot of benefits – the tool enables us to better balance workload, have a constant view of what people are doing. I really recommend it, I evaluated a lot of tools, also had an in-house development before which demanded a lot of maintenance, and actiTIME solved all problems with no hassle.

Try actiTIME

If you run trials for clients, our guide to actiTIME for CRO operations walks through the setup, and we have written separately about the operational challenges CROs face.

How to choose

Work out which categories apply to you before you compare any products. Almost nobody needs all eleven, and the organizations that buy all eleven early are usually the ones that regret it. The mix depends less on company size than on which side of the trial you sit on.

• A single research site? Needs a CTMS, an eRegulatory system, and cost or time tracking. The EDC, eTMF, RTSM, and safety database all belong to the sponsor side, configured per protocol and handed to the site, not purchased by it.
• A small or early-phase sponsor running one or two studies at a time? Usually starts with a bundled eClinical platform that covers data capture, consent, and outcomes in one subscription, adds a safety database once a product reaches post-marketing surveillance, and can often run randomization inside the EDC itself before a dedicated RTSM earns its keep.
• A large sponsor running many concurrent trials? Needs the full sponsor-side stack – EDC, eTMF, RTSM, safety database, eCOA – plus participant payments and recruitment tooling at scale. Cost and time visibility across studies turns into a portfolio-level question here, the kind a board asks about, not a bookkeeping detail.
• A CRO serving multiple sponsors? Needs to plug into whichever EDC or eTMF each client already runs, since standardizing on one vendor across clients rarely works, plus its own CTMS and cost tracking to manage margin across contracts.
• Running oncology, CNS, or rare disease trials? Therapeutic area can override company size here: complex dosing and fragile supply chains usually justify a heavier RTSM investment even at a small sponsor.

Once the category list is settled, the harder part starts: making the chosen tools work inside existing workflows and regulatory obligations. That is an implementation question, and it carries its own set of risks.

How to implement

Picking a category and a vendor is the easy half. Clinical trial systems carry a compliance obligation most business software never has to meet: under 21 CFR Part 11 and ICH E6(R3), the sponsor or CRO stays responsible for validating a system as fit for purpose and governing how it gets used, even when the vendor hosts it. Part 11 compliance supports Good Clinical Practice rather than replacing it – the point is making sure the electronic records a system produces can stand up to monitoring, audits, and inspection.

In practice that means a handful of steps beyond signing the contract: write or update the SOPs that govern the new system, train staff on both GCP and the system’s specific Part 11 controls instead of a general refresher, review the system periodically for compliance risk beyond the initial go-live check, and build audit readiness into routine operation so documentation never needs reconstructing later. ICH E6(R3)’s 2025 update pushes toward a risk-proportionate approach to this validation work, but it also names the ongoing burden of keeping EDC and eConsent platforms audit-ready as a genuine, recurring resource cost.

Adoption still lags what the marketing pages suggest. Veeva’s 2025 MedTech Clinical Benchmark Report found CTMS adoption at 38 percent among smaller or emerging companies versus 72 percent at enterprise scale, with EDC adoption at 62 percent versus 71 percent over the same split – a survey of MedTech trials specifically, so treat it as a reality check on how far “everyone has this” sits from the truth, not a figure for the whole clinical market. The same report found site identification and selection cited by 37 percent of respondents as the single biggest trial start-up bottleneck, ahead of any system choice.

A few practical habits separate a smooth rollout from a stalled one: involve the coordinators and site staff who will use the system daily before configuration starts; budget for data migration and training as their own line items instead of folding them into the license cost; and fit the system to how the trial already runs, since forcing staff to adopt a new workflow at the same time as a new tool is how rollouts stall. No independent benchmark exists for how long a given rollout actually takes, only vendor-quoted timelines that reflect each vendor’s own best case. Pilot on one protocol before committing a whole portfolio to a new system.

Frequently asked questions

What is clinical trial software?

Clinical trial software is not one product but a category of systems used to design, run, and report a clinical study. The main categories are electronic data capture for participant data, a trial master file for regulatory documents, a clinical trial management system for site operations, randomization and supply management, patient outcome collection, a safety database, and supporting tools for consent, recruitment, payments, and cost tracking.

What is the difference between an EDC and a CTMS?

An EDC captures the clinical data collected from participants, such as lab values, adverse events, and visit outcomes. A CTMS manages the operational business of running the study, covering recruitment, visit scheduling, staff tasks, budgets, and site payments. They answer different questions, and most organizations running trials at any scale need both.

How many of these categories do we actually need?

It depends entirely on your role. A single research site typically needs a CTMS, an eRegulatory system, and a way to track time and cost, while using whatever EDC each sponsor mandates. A sponsor needs the EDC, eTMF, RTSM, safety database, and eCOA, and generally never touches a site CTMS. Buying categories you have not grown into is the most common mistake in this market.

How much does clinical trial software cost?

None of the clinical vendors covered here publish list pricing. Quotes are built around the number of studies, sites, and users, plus which modules you enable, and enterprise platforms typically carry implementation and validation costs on top of licensing. Expect a scoping conversation with each shortlisted vendor. You will not find published prices to compare. actiTIME is the exception, with pricing published openly.

Where does time tracking fit into a clinical trial stack?

Trial platforms record what happened to patients. They rarely record what the work cost. A time tracking tool sits alongside the EDC and CTMS, attributing staff hours to specific studies and converting them into cost, billable amounts, and margin. For contract research organizations billing sponsors, and for sites deciding which trials to accept, that information determines profitability.

Getting started

Whichever platforms run the trial, the hours behind them still need accounting for. Learn how to set up time tracking in five steps, or sign up free: a permanent plan for up to 3 users, or a full-featured 30-day trial, both at no cost.